Genesis Sample Clauses

Genesis. 11.2.1.1 Verizon will provide an appropriate EMI record to Genesis; and
Genesis. GENESIS ACOUSTICS is a high-tech company founded in 1999 (SME), spin-off from CNRS-LMA. Its main activities are Sound Simulation, Sound Perception, and Sound Design and its main markets are the automotive (Renault, PSA, Volkswagen, Hyundai, Nissan, etc.) and the aeronautic industries (Airbus, Eu- rocopter, Dassault Aviation, Snecma, etc.). GENESIS spends more than 30 % of its activities in Research and Development projects (FUI, EC FP7 projects). GENESIS received an Award from the SFA (Société Française d’Acoustique) in 2005 for its technologies and involvement in research projects. The key know- hows of GENESIS are: • Signal Processing, software development, real-time sound simulators • 3D sound and virtual reality • Psychoacoustics • Speech intelligibility Among other realizations, GENESIS has developed LEA, a tool for sound quality assessment and sound design used by Dassault, Airbus, Snecma, Eurocopter. GENESIS was also expert on EC FP7 project, formerly SEFA and now COSMA (Xxxxxxx Xxxxxxxx), about the sound simulation of aircraft and sound perception for community around airports. Key staff Xxxxxxx Xxxxxxxx (Local Manager) is the executive director and founder of GENESIS. He re- ceived master’s degree in engineering from l’École Nationale des Arts and a master’s degree in acous- tics from the University of Aix-Marseille (1991). He has worked with the Laboratoire de Mécanique et d’Acoustique (LMA) du CNRS and for real-time sound simulation. Xxxxxxxxxx Xxxxxxxx is the technical director of GENESIS. He received a PhD degree in acoustics from the Université du Maine (1997, physical modeling of boards). He has worked for several acoustical engi- neering agencies and joined GENESIS in 2008. His specialties include signal processing, sound perception, microphone array design, speech intellegibillity. Xxxxxxxxx Xxxxxxxx received a Ph.D in Acoustics from the Université du Maine (Le Mans) in 2004. Since 2000, he has been involved in several projects with IRCAM. He has worked with the department of Psychology at Carnegie Mellon University (Pittsburgh, PA) and with Davide Rocchesso at IUAV. His research activities include psychoacoustics, perception and cognition of sound sources, and vocal imitations of sounds.
Genesis. Genesis recognizes and acknowledges that it has in the past, currently has, and prior to the Effective Time will have, access to certain confidential information of Company, such as lists of customers, operational policies, pricing and cost policies that are valuable, special and unique assets of Company and Company's business. Genesis agrees that it will not disclose any confidential information to any person, firm, corporation, association, or other entity for any purpose or reason whatsoever, prior to the Effective Time without prior written consent of Stockholder. In the event of a breach or threatened breach by Genesis of the provisions of this Section 7.12, Stockholder shall be entitled to an injunction restraining Genesis from disclosing, in whole or in part, such confidential information. Nothing contained herein shall be construed as prohibiting Stockholder from pursuing any other available remedy for such breach or threatened breach, including the recovery of damages.
Genesis. Develop, implement and evaluate GMP procedures for the large scale production of TIL suitable for infusion into patients with metastatic melanoma. - Consult with the FDA to determine the appropriate clinical trial design necessary to secure approval for the commercial development of TIL therapy for patients with metastatic melanoma and sponsor the IND for this new clinical protocol Serve as the coordinating center for the multicenter licensing clinical trial. - Supply TIL in sufficient quantities to the NCI Surgery Branch and other multicenter sites to complete the planned clinical trials (including the licensing trial) needed for FDA approval of ACT/TIL. Support the establishment of a central facility for the processing and provision of TIL for the studies under this CRADA. Surgery Branch, NCI and Genesis - Develop SOP for large scale TIL growth, selection and testing to support the FDA approval of the ACT/TIL therapy approach. Attend joint meetings with the FDA to define the exact format and criteria needed in the clinical trial(s) to obtain FDA approval. - Develop, conduct and evaluate a multiinstitutional clinical trial (to include the NCI Surgery Branch as a clinical trial site) for patients with metastatic melanoma treated with TIL that can be used as a licensing trial required for FDA approval and subsequent commercialization of ACT/TIL. PHS ICT-CRADA Case Ref. No. _______ MODEL ADOPTED June 18, 2009 - Exchange information and expertise to further the successful development of TIL therapy for patients with metastatic melanoma. Related NCI and Collaborator Agreements: None Related Intellectual Property and Business/Scientific Expertise of the Parties NCI Surgery Branch
Genesis. Guiding principle of all openMedicine work was to optimise health services for patients, in- clud-ing ePrescriptions and their dispensation abroad. Due to different marketing authorisa- tion pro-cedures for medicinal products, different marketing strategies of pharmaceutical companies, shortages and other factors, successfully dispensing a foreign ePrescription regularly involves identification issues, which sometimes may become complex, and requires substitution where permitted – or as an alternative a new visit to a local prescriber. Based on all earlier work, particularly the results of work-packages 2, 3, and 5, and the sum- xxxx discussion above, this chapter presents and elaborates the various recommendations identified by the consortium. These recommendations are intended to complement ongoing work at the level of national, European and international competent authorities and organisa- tions. The recommendations provide suggestions particularly in domains where European Un-ion issues, challenges and interests are at stake. The further development and imple- mentation of ISO IDMP by relevant players and stakeholders across the Union is mandatory for solving the core challenges around the univocal identification of medicinal products in cross-border healthcare as identified by the epSOS pilot services. The ongoing and planned eHealth service applications in the context of the “Connecting Europe Facility (CEF)” initiative will benefit from the realisation of these recommendations. IDMP implementation will impact both the regulatory and clinical realms, and contribute fundamentally to improved patient xxxxx for the citizens of Europe. Furthermore, national, Union-wide and international electronic health data interoperability will indeed become achieveable with respect to medica-tion data in ePrescriptions, ePatient Summaries, Electronic Health Records and other docu-ments and messages. Regulatory processes of registration, authorisation and marketing of new medicinal products will be streamlined across their whole life cycle, pharmacovigilance improved, and better patient information facilitated. The recommendations to follow were developed by the openMedicine team, discussed in de-tail at a two-day face-to-face meeting, presented and extensively explored with the ple- num of the expert council attached to this project at its final meeting in London in November of 2016 as well as afterwards with individual persons. They were and edited by the an edito- ...
Genesis. (g) with respect to each MSA Aircraft Asset acquired on or after the date hereof, the relevantSeller Indemnitees” (as defined in the applicable asset purchase agreement) during the period commencing on the date of delivery of such MSA Aircraft Asset and ending on the earlier of (i) the second anniversary of such date of delivery and (ii) the date of completion of the next major check in respect of such MSA Aircraft Asset. ANNEX 2 TO THE SERVICING AGREEMENT APPENDIX A TO THE SERVICING AGREEMENT CONSTRUCTION AND USAGE; DEFINITIONS

Related to Genesis

  • Cornerstone shall notify the LLC and confirm such advice in writing (i) when the filing of any post-effective amendment to the Registration Statement or supplement to the Prospectus is required, when the same is filed and, in the case of the Registration Statement and any post-effective amendment, when the same becomes effective, (ii) of any request by the Securities and Exchange Commission for any amendment of or supplement to the Registration Statement or the Prospectus or for additional information and (iii) of the entry of any stop order suspending the effectiveness of the Registration Statement or the initiation or threatening of any proceedings for that purpose, and, if such stop order shall be entered, Cornerstone shall use its best efforts promptly to obtain the lifting thereof.

  • HORIZONR Gateway HORIZONR Gateway provides customers with the ability to (i) generate reports using information maintained on the Multicurrency HORIZONR Accounting System which may be viewed or printed at the customer’s location; (ii) extract and download data from the Multicurrency HORIZONR Accounting System; and (iii) access previous day and historical data. The following information which may be accessed for these purposes: 1) holdings; 2) holdings pricing; 3) transactions, 4) open trades; 5) income; 6) general ledger and 7) cash.

  • Operating Partnership Operating Partnership shall have the meaning set forth in the preamble of this Agreement.

  • MODERN SLAVERY You hereby affirm your compliance with the Modern Slavery Xxx 0000 and associated guidance. You confirm (a) that you have read, are familiar with and shall not perform an act or omission which is in contravention with, the letter or spirit of the Act; and (b) you carry out regular, meaningful and comprehensive due diligence procedures and have internal policies in place to address any suspected human rights abuse in your business and Group where applicable.

  • Millwright The rest period provided for under Paragraph c) of this Subsection is eliminated to allow an employee to finish work 15 minutes earlier, or it may be worked and paid at the applicable wage rate.

  • Asset Management Supplier will: i) maintain an asset inventory of all media and equipment where Accenture Data is stored. Access to such media and equipment will be restricted to authorized Personnel; ii) classify Accenture Data so that it is properly identified and access to it is appropriately restricted; iii) maintain an acceptable use policy with restrictions on printing Accenture Data and procedures for appropriately disposing of printed materials that contain Accenture Data when such data is no longer needed under the Agreement; iv) maintain an appropriate approval process whereby Supplier’s approval is required prior to its Personnel storing Accenture Data on portable devices, remotely accessing Accenture Data, or processing such data outside of Supplier facilities. If remote access is approved, Personnel will use multi-factor authentication, which may include the use of smart cards with certificates, One Time Password (OTP) tokens, and biometrics.

  • Healthcare Without limiting or being limited by any other provision of any Loan Document, Borrower has timely filed or caused to be filed all cost and other reports of every kind required under any Healthcare Laws or any provider or other agreement relating to Borrower’s participation in Medicare or Medicaid programs. Subject to subsection (a)(x) of Section 5.20, there are no claims, actions or appeals pending (and Borrower has not filed any claims or reports which could reasonably result in any such claims, actions or appeals) before any commission, board or agency or other Governmental Authority, including, without limitation, any intermediary or carrier, the Provider Reimbursement Review Board or the Administrator of the Centers for Medicare and Medicaid Services, with respect to any state or federal Medicare or Medicaid cost reports or claims filed by Borrower, or any disallowance by any commission, board or agency or other Governmental Authority in connection with any audit of such cost reports. No validation review or program integrity review related to Borrower or the consummation of the transactions contemplated herein or to the Collateral have been conducted by any commission, board or agency or other Governmental Authority in connection with the Medicare or Medicaid programs, and to the knowledge of Borrower, no such reviews are scheduled, pending or threatened against or affecting any of the providers, any of the Collateral or the consummation of the transactions contemplated hereby.

  • Business Partners Red Hat has entered into agreements with other organizations (“Business Partners”) to promote, market and support certain Software and Services. When Client purchases Software and Services through a Business Partner, Red Hat confirms that it is responsible for providing the Software and Services to Client under the terms of this Agreement. Red Hat is not responsible for (a) the actions of Business Partners, (b) any additional obligations Business Partners have to Client, or (c) any products or services that Business Partners supply to Client under any separate agreements between a Business Partner and Client.

  • Acquisition Corp Acquisition Corp. is a wholly-owned Delaware subsidiary of Parent that was formed specifically for the purpose of the Merger and that has not conducted any business or acquired any property, and will not conduct any business or acquire any property prior to the Closing Date, except in preparation for and otherwise in connection with the transactions contemplated by the Merger Documents and the other agreements to be made pursuant to or in connection with the Merger Documents.

  • Games The Private Party shall not be entitled to introduce any arcade type amusement or gaming machines into the Restaurant Facility without the prior written approval of SANParks.